Haemonetics (NYSE: HAE) announced today that it acquired percutaneous vessel closure device maker Vivasure Medical.

Researchers have found in a new study that the novel Lesifter device shows encouraging early efficacy and a favorable safety profile in reducing stroke risk among patients with atrial ...

NEW YORK, Jan. 3, 2025 /PRNewswire/ -- Report on how AI is driving market transformation - The global endoscopic closure devices market size is estimated to grow by USD 825.7 million from 2025-2029, ...

CHARLOTTE, N.C., March 27, 2025 /PRNewswire/ -- Vasorum USA, Inc, a privately held, commercial-stage medical device company dedicated to redefining vascular closure, today announced U.S. Food and Drug ...

BOSTON, June 18, 2024 /PRNewswire/ -- Haemonetics Corporation (HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, has launched a ...

Able Medical’s sternal closure system utilizes PEEK (polyether ether ketone) to provide surgeons with a strong, lightweight ...

BURLINGTON, MA — An active surveillance system now available as an open-source tool found that the relative risk of vascular complications was increased 60% for patients receiving Mynx (Cardinal ...

BOSTON, Oct. 24, 2025 /PRNewswire/ -- Intrinsic Therapeutics, Inc., the makers of the Barricaid® Annular Closure Device, announced today that the American Medical Association (AMA) has published a new ...

Results of the Embolic Protection in Patients with Atrial Fibrillation (PROTECT-AF) showed that in AF patients who were candidates for warfarin therapy, device closure of the LAA using the Watchman ...

Haemonetics will shell out up to 185 million euros ($216 million) to acquire Vivasure Medical, a Galway, Ireland-based medtech that makes arterial closure devices.

SAN FRANCISCO -- Surprisingly, a course of direct oral anticoagulation (DOAC) may be the safer choice for antithrombotic treatment after left atrial appendage (LAA) occlusion, according to the ANDES ...